234 related articles for article (PubMed ID: 11303049)
1. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.
Junot C; Gonzales MF; Ezan E; Cotton J; Vazeux G; Michaud A; Azizi M; Vassiliou S; Yiotakis A; Corvol P; Dive V
J Pharmacol Exp Ther; 2001 May; 297(2):606-11. PubMed ID: 11303049
[TBL] [Abstract][Full Text] [Related]
2. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
4. Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme.
Jullien ND; Cuniasse P; Georgiadis D; Yiotakis A; Dive V
FEBS J; 2006 Apr; 273(8):1772-81. PubMed ID: 16623712
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.
Junot C; Nicolet L; Ezan E; Gonzales MF; Menard J; Azizi M
J Pharmacol Exp Ther; 1999 Dec; 291(3):982-7. PubMed ID: 10565814
[TBL] [Abstract][Full Text] [Related]
7. In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis.
Junot C; Menard J; Gonzales MF; Michaud A; Corvol P; Ezan E
J Pharmacol Exp Ther; 1999 Jun; 289(3):1257-61. PubMed ID: 10336514
[TBL] [Abstract][Full Text] [Related]
8. Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production.
Azizi M; Junot C; Ezan E; Hallouin MC; Guyene T; Ménard J
J Mol Med (Berl); 2002 Aug; 80(8):492-8. PubMed ID: 12185449
[TBL] [Abstract][Full Text] [Related]
9. Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype.
van Esch JH; van Gool JM; de Bruin RJ; Payne JR; Montgomery HE; Hectors M; Deinum J; Dive V; Jan Danser AH
J Hypertens; 2008 Apr; 26(4):706-13. PubMed ID: 18327080
[TBL] [Abstract][Full Text] [Related]
10. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
[TBL] [Abstract][Full Text] [Related]
11. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo.
Rousseau-Plasse A; Wdzieczak-Bakala J; Lenfant M; Ezan E; Genet R; Robinson S; Briscoe T; Melville J; Riches A
Exp Hematol; 1998 Oct; 26(11):1074-9. PubMed ID: 9766448
[TBL] [Abstract][Full Text] [Related]
12. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.
Dive V; Cotton J; Yiotakis A; Michaud A; Vassiliou S; Jiracek J; Vazeux G; Chauvet MT; Cuniasse P; Corvol P
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4330-5. PubMed ID: 10200262
[TBL] [Abstract][Full Text] [Related]
13. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
[TBL] [Abstract][Full Text] [Related]
14. The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans.
Wuerzner G; Peyrard S; Blanchard A; Lalanne F; Azizi M
J Hypertens; 2009 Jul; 27(7):1404-9. PubMed ID: 19506528
[TBL] [Abstract][Full Text] [Related]
15. Development of domain-selective angiotensin I-converting enzyme inhibitors.
Redelinghuys P; Nchinda AT; Sturrock ED
Ann N Y Acad Sci; 2005 Nov; 1056():160-75. PubMed ID: 16387685
[TBL] [Abstract][Full Text] [Related]
16. Coumarin-Ser-Asp-Lys-Pro-OH, a fluorescent substrate for determination of angiotensin-converting enzyme activity via high-performance liquid chromatography.
Cheviron N; Rousseau-Plasse A; Lenfant M; Adeline MT; Potier P; Thierry J
Anal Biochem; 2000 Apr; 280(1):58-64. PubMed ID: 10805521
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory action of the peptide AcSDKP on the proliferative state of hematopoietic stem cells in the presence of captopril but not lisinopril.
Chisi JE; Wdzieczak-Bakala J; Riches AC
Stem Cells; 1997; 15(6):455-60. PubMed ID: 9402658
[TBL] [Abstract][Full Text] [Related]
18. Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design.
Douglas RG; Ehlers MR; Sturrock ED
Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):535-41. PubMed ID: 23351021
[TBL] [Abstract][Full Text] [Related]
19. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Michaud A; Williams TA; Chauvet MT; Corvol P
Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides.
Cotton J; Hayashi MA; Cuniasse P; Vazeux G; Ianzer D; De Camargo AC; Dive V
Biochemistry; 2002 May; 41(19):6065-71. PubMed ID: 11994001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
